Home › Trial NCT05563272
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- Trial IDNCT05563272
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorTelix Pharmaceuticals (Innovations) Pty Ltd
- Enrollment11
- Start date2023-06-06
- ConditionsCervical Cancer · Colorectal Cancer · Esophageal Cancer · Gastric Cancer · Glioblastoma Multiforme · Cholangiocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.